Spoken Alpha
Edgewise Therapeutics, Inc.
Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat rare neuromuscular and cardiac diseases. The company's lead program, sevasemten, is an oral myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies.
Edgewise Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $4.82B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 4, 2026).
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add EWTX, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for EWTX.
$ curl https://api.spokenalpha.com/v1/companies/EWTXFAQ
Spoken Alpha indexes EWTX's earnings call transcripts at https://spokenalpha.com/companies/EWTX. Each call links to attributed speakers and parsed analyst Q&A. Edgewise Therapeutics, Inc.'s own investor relations page is at https://investors.edgewisetx.com/overview/default.aspx.
Edgewise Therapeutics, Inc. (EWTX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-04 | — | $-0.55 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-05 | $-0.53 | $-0.48 | -10.4% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-06 | $-0.46 | $-0.48 | +4.2% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-02-25 | $-0.47 | $-0.43 | -9.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-05 | $-0.39 | $-0.40 | +2.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.34 | $-0.42 | +19.1% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.43 | $-0.42 | -2.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $-0.42 | $-0.42 | +0.5% | $2.1M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.36 | $-0.37 | +2.7% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.34 | $-0.34 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-0.33 | $-0.41 | +19.5% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.47 | $-0.43 | -9.3% | $2.3M | — | — | EODHD |
| Q3 FY2023 | 2023-11-08 | $-0.41 | $-0.40 | -2.5% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-09 | $-0.34 | $-0.40 | +15.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.36 | $-0.35 | -2.9% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-02-22 | $-0.31 | $-0.33 | +6.1% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.34 | $-0.36 | +5.6% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.32 | $-0.32 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-10 | $-0.30 | $-0.28 | -7.1% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-23 | $-0.26 | $-0.25 | -4.0% | $0 | — | — | EODHD |
Source: EODHD. EWTX reported actuals as published; sparse fields render as —.